Mast cells, which are abundant in the airways of asthmatic individuals, act as first responders to viral infections by ...

Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

Dupilumab rapidly treated and maintained improvements in lichenification, a type of skin thickening from repetitive ...

Dupilumab is designed to decrease type 2 inflammation in patients with bullous pemphigoid by targeting 2 key inflammatory cytokines, interleukin-4 and interleukin-13. The sBLA was supported by ...

In this randomized, placebo-controlled replicate trial, depemokimab decreased the annual rate of exacerbations among patients ...